Final Preclinical Data on Thetis’ TP-113 Showing Reduced Insulin Resistance Presented at ICCR

Share Article

TP-113, a novel oral anti-diabetes drug candidate, delivers both metformin and DHA from a single new chemical entity.

Thetis Pharmaceuticals

TP-113 delivers both metformin and DHA from a single new chemical entity, which enables a unique product profile that is quite differentiated from current oral anti-diabetic drugs that do not address insulin resistance.

Thetis Pharmaceuticals, LLC (“Thetis”), a privately held biopharmaceutical company developing products for treatment of cardiometabolic and other diseases, today announced the presentation of data on TP-113, a novel oral anti-diabetes drug candidate with the potential to reduce insulin resistance, decrease hepatic glucose output, and reduce plasma triglycerides. Thetis collaborators at Laval University presented data on TP-113 and its mechanistic effects on the myokine-hepatic glucoregulatory axis at the 5th Annual ICCR Congress on Chronic Societal Cardiometabolic Diseases in Quebec City.

“TP-113 is an innovative small molecule that delivers both metformin and DHA from a single new chemical entity, which enables a unique product profile that is quite differentiated from current oral anti-diabetic drugs that do not address insulin resistance and elevated lipid levels,” said Frank C. Sciavolino, Ph.D., Thetis co-founder and CSO. “In addition, we believe that TP-113 has prospects for achieving cardiovascular risk reduction in obese type 2 diabetic patients, a benefit that is not available in any approved oral anti-diabetic drug. TP-113 has the potential to become a breakthrough product in addressing the principal cause of morbidity and mortality in this patient population.”

Thetis collaborator and scientific advisor, Andre Marette, Ph.D., Professor of Medicine, Laval University, Quebec, Canada, elaborated on TP-113’s prospects as a potential diabetes drug. In an oral presentation, he described the previously unrecognized glucoregulatory activity of DHA and discussed how DHA metabolite protectin DX (PDX) acts as a critical signaling molecule that enables glucose uptake in skeletal muscle and the down-regulation of hepatic glucose output. In his presentation, Dr. Marette reported data showing that “TP-113 treatment raises DHA and PDX levels in skeletal muscle and that long-term oral treatment with TP-113 reduces insulin resistance in db/db mice as compared to vehicle treatment. We conclude that TP-113 improves insulin sensitivity in obese diabetic mice in association with activation of the PDX signaling axis.”

Dr. Sciavolino noted, “Based on the data generated by Dr. Marette’s laboratory showing that TP-113 reduces insulin resistance, Thetis will advance this novel candidate into the clinic, targeting a proof of concept insulin clamp study in diabetic patients in early 2017.”

About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a privately held biopharmaceutical company applying its expertise in amino-lipid chemistry to discover and develop innovative drugs for the treatment of cardiometabolic and other diseases. Thetis uses its proprietary HEALER platform to transform approved drugs or previously studied biologically active agents into new chemical entities with better pharmacokinetic, pharmacodynamic or physico-chemical properties, thereby enhancing their efficacy, tolerability and patient convenience. This approach enables the development of known agents for new, previously unattainable indications and offers an approach to drug discovery and clinical development that is potentially more efficient and less expensive than conventional small molecule drug research and development. Thetis is implementing this approach to develop a robust pipeline of potential new medicines targeting major and rare diseases.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Linn
Linnden Communications
+1 (774) 696-3803
Email >
Visit website